Turnover, Dissension, And Isolation Plague NSF Office That Monitors Health Of Science

Employees say cronyism and inconsistent leadership have seriously damaged the unit charged with keeping tabs on U.S. research WASHINGTON--The division within the National Science Foundation that monitors the health of the United States' scientific infrastructure is in a state of turmoil, according to knowledgeable sources and internal documents obtained by The Scientist. At the heart of the unrest, these sources allege, are conflicts of interest and favoritism in the awarding of contracts, ins

Written byJeffrey Mervis
| 14 min read

Register for free to listen to this article
Listen with Speechify
0:00
14:00
Share

The unrest threatens to reverberate far beyond the 47 employees of the division and the $6 million in contracts that it will award this year for reports on such issues as federal spending on research, the state of academic facilities and instrumentation, and trends in scientific personnel. Those who follow the division's efforts say that the problems, if allowed to continue, could delay publication, and even undermine the accuracy, of SRS data. Federal policymakers, among others, rely upon these findings for an accurate picture of the condition of science in the U.S.--a picture whose clarity they depend on when allocating funds to the research community.

There is general agreement that a revolving door at the top--the division has had four directors in the past 18 months--has aggravated the problem. Some of the directors, appointed with a mandate to straighten things out, have instead, according to sources, become victims of power ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies